Galectin-3 is an FDA-cleared blood test available for clinical use in chronic heart failure.
-
Galectin-3 Testing
The BGM Galectin-3 Blood Test is FDA-cleared as an aid in assessing the prognosis of CHF patients*.
* in conjunction with clinical evaluation.
-
Prevalance of Galectin-3 Mediated HF
30–50% of CHF patients have a common and serious form of heart failure known as galectin-3 mediated heart failure.
-
Impact of Galectin-3 Mediated HF
“Galectin-3 testing may be of benefit in programs aiming to reduce hopital readmission rates for HF.”
Rudolf A. De Boer, MD. PHD
University Medical Center Groningen, Groningen NL
-
Galectin-3 in Chronic HF
Galectin-3 defines a distinct form of heart failure characterized by progressive fibrosis.
Learn more at the HFA meeting in Lisbon – register now!
Galectin-3 mediated heart failure
The Disease
Heart failure is a condition caused by multiple medical problems and risk factors. Studies have shown that in 30–50% of chronic heart failure patients there is an underlying and inherently progressive disease mediated by the protein galectin-3.
The Impact
In the US alone, heart failure is expected to cost the healthcare system over an estimated $39 billion. A significant contributor is the rehospitalization rate of 40% for HF patients. Galectin-3 was found to be a strong independent predictor of rehospitalization for HF patients.
The Test
In 2010, the BGM Galectin-3 blood test became the first novel cardiovascular in-vitro diagnostic test to be cleared by the FDA in more than five years. The assay, which measures galectin-3 protein levels, can be used to assess the prognosis of HF patients.
News & Events
-
BG Medicine, Inc. Announces Publication of Important Galectin-3 Study Designed to Identify Adults in General Population at Risk for Heart Failure
Study Reports in Journal of American College of Cardiology That Those in General Population With Elevated Galectin-3 Levels Have Significantly Increased Risk of Developing Heart Failure WALTHAM, Mass., Aug. 30, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the study, [...]
Aug 30, 2012
-
BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Atherotech Diagnostics Lab
WALTHAM, Mass., June 18, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Atherotech Diagnostics Lab (Atherotech) now offers galectin-3 testing services to its laboratory customers and physicians. To offer galectin-3 testing, Atherotech is using the BGM Galectin-3™ test, which was [...]
Jun 18, 2012
Get the latest updates
Loading ...
